Editors’ Choice papers in Thrombosis and Haemostasis

References
1 Lip GY, Andreotti F, Fauchier L. et al. European Heart Rhythm Association.. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
2 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584. DOI:10.1160/TH11-04-0262.
3 Pengo V, Crippa L, Falanga A. et al. Italian Federation of Thrombosis Centers.. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
4 Korte W, Cattaneo M, Chassot PG. et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-749. DOI:10.1160/TH10-04-0217.
5 Ylä-Herttuala S, Bentzon JF, Daemen M. et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2011; 106: 1-19. DOI:10.1160/TH10-12-0784.
6 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065. DOI:10.1160/TH11-11-0768.
7 Kirchhof P, Lip GY, Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106: 1012-1019. DOI:10.1160/TH11-07-0517.
8 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-567. DOI:10.1160/TH11-08-0602.
9 Lip GY, Piotrponikowski P, Andreotti F. et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. An Executive Summary of a joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012; 108: 1009-1022. DOI:10.1160/TH12-08-0578.
10 Quercioli A, Mach F, Bertolotto M. et al. Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost 2012; 107: 124-139. DOI:10.1160/TH11-05-0324.
11 Lutgens E, Leiner T, Weber C. RANK(L)-ing biomarkers as surrogates for coronary calcium score. Thromb Haemost 2012; 107: 3. DOI:10.1160/TH11-11-0775.
12 Ekström M, Liska J, Eriksson P. et al. Stimulated in vivo synthesis of plasminogen activator inhibitor-1 in human adipose tissue. Thromb Haemost 2012; 108: 485-492. DOI:10.1160/TH11-11-0822.
13 Preissner KT. Adipose tissue-derived PAI-1: a molecular link for thrombo-inflammatory disease states?. Thromb Haemost 2012; 108: 415. DOI:10.1160/TH12-08-0540.
14 Sibbing D, Byrne RA, Bernlochner I. et al. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011; 106: 191-202. DOI:10.1160/TH11-01-0040.
15 Etulain J, Negrotto S, Carestia A. et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 2012; 107: 99-110. DOI:10.1160/TH11-06-0443.
16 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl. 01) S34-42. DOI:10.1160/THS10-11-0717.
17 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-33. DOI:10.1160/THS10-11-0720.
18 Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost 2011; 106: 763-771. DOI:10.1160/TH11-05-0320.
19 Manthey HD, Zernecke A. Dendritic cells in atherosclerosis: functions in immune regulation and beyond. Thromb Haemost 2011; 106: 772-778. DOI:10.1160/TH11-05-0296.
20 Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762. DOI:10.1160/TH11-07-0500.
21 Gray C, Loynes CA, Whyte MK. et al. Simultaneous intravital imaging of macrophage and neutrophil behaviour during inflammation using a novel transgenic zebrafish. Thromb Haemost 2011; 105: 811-819. DOI:10.1160/TH10-08-0525.
22 Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear stress-regulated microRNAs. Thromb Haemost 2012; 108: 616-620. DOI:10.1160/TH12-07-0491.
23 Bidzhekov K, Gan L, Denecke B. et al. microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans. Thromb Haemost 2012; 107: 619-625. DOI:10.1160/TH11-09-0607.
24 Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial remodelling. Thromb Haemost 2012; 107: 611-618. DOI:10.1160/TH11-12-0826.
25 Matusik P, Guzik B, Weber C. et al. Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?. Thromb Haemost 2012; 108: 443-456. DOI:10.1160/TH12-05-0341.
26 Sagan A, Mrowiecki W, Mikolajczyk TP. et al. Local inflammation is associated with aortic thrombus formation in abdominal aortic aneurysms. Relationship to clinical risk factors. Thromb Haemost 2012; 108: 812-823. DOI:10.1160/TH12-05-0339.
27 Nowak WN, Mika P, Nowobilski R. et al. Exercise training in intermittent claudication: Effects on antioxidant genes, inflammatory mediators and proangiogenic progenitor cells. Thromb Haemost 2012; 108: 824-831. DOI:10.1160/TH12-04-0278.
28 McNeill E, Channon K. The role of tetrahydrobiopterin in inflammation and cardiovascular disease. Thromb Haemost 2012; 108: 832-839. DOI:10.1160/TH12-06-0424.
29 Geenen IL, Post MJ, Molin DG. et al. Coagulation on endothelial cells: The underexposed part of Virchow’s Triad. Thromb Haemost 2012; 108: 863-871. DOI:10.1160/TH12-04-0269.
30 Roldán V, Marín F. Pro: “Antidote for new anticoagulants” - Specific target of inhibition requires a specific target for neutralisation. Thromb Haemost 2012; 108: 621-622. DOI:10.1160/TH12-06-0440.
31 Eerenberg ES, Levi M, Büller HR.. Contra: “Antidotes for novel anticoagulants?” -Do we really need them. Thromb Haemost 2012; 108: 623-624. DOI:10.1160/TH12-05-0298.
32 Serebruany VL. Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027. DOI:10.1160/TH12-03-0180.
33 Schrör K. ‘Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel’ - a hypothesis that remains unproven. Thromb Haemost 2012; 108: 1028-1030. DOI:10.1160/TH12-07-0513.
34 Verheugt FW. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Editorial on Serebruany, Atar: ‘Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?’ (Thromb Haemost 2012; 108.3). Thromb Haemost 2012; 108: 410-411.
35 Serebruany VL, Atar D. Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?. Thromb Haemost 2012; 108: 412-414. DOI:10.1160/TH12-04-0251.
36 Eriksson BI, Dahl OE, Huo MH. et al. RE-NOVATE II Study Group.. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
37 Turpie AG, Lassen MR, Eriksson BI. et al. Thromb Haemost. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453. DOI:10.1160/TH10-09-0601.
38 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749. DOI:10.1160/TH11-05-0364.
39 Lindahl TL, Baghaei F, Blixter IF. et al. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden.. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
40 Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrialfibrillation. Thromb Haemost 2012; 108: 476-484. DOI:10.1160/TH12-02-0093.
41 Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME. et al. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 106: 539-547. DOI:10.1160/TH11-02-0069.
42 Auwerda JJ, Yuana Y, Osanto S. et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost 2011; 105: 14-20. DOI:10.1160/TH10-03-0187.
43 Harenberg J, Marx S, Wehling M. Head-to-head or indirect comparisons of the novel oral anticoagulants in atrialfibrillation: what’s next?. Thromb Haemost 2012; 108: 407-409. DOI:10.1160/TH12-07-0463.
44 Skjøth F, Larsen TB, Rasmussen LH. Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation. Thromb Haemost 2012; 108: 405-406. DOI:10.1160/TH12-06-0438.
45 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589. DOI:10.1160/TH11-11-0784.
46 Sorensen SV, Kansal AR, Connolly S. et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908-919. DOI:10.1160/TH11-02-0089.
47 Chung N, Jeon HK, Lien LM. et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011; 105: 535-544. DOI:10.1160/TH10-07-0451.
48 Salazar DE, Mendell J, Kastrissios H. et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925-936. DOI:10.1160/TH11-08-0566.
49 Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?. Thromb Haemost 2011; 105: 574-578. DOI:10.1160/TH10-12-0808.
50 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost 2011; 106: 528-538. DOI:10.1160/TH11-02-0061.
51 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179. DOI:10.1160/TH12-03-0175.
52 Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011; 105: 396-408. DOI:10.1160/TH10-09-0595.
53 Suades R, Padró T, Vilahur G. et al. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108: 1208-1219. DOI:10.1160/TH12-07-0486.
54 Richter B, Koller L, Hohensinner PJ. et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012; 108: 1220-1227. DOI:10.1160/TH12-03-0195.
55 Lenglet S, Thomas A, Chaurand P. et al. Molecular imaging of matrix metalloproteinases in atherosclerotic plaques. Thromb Haemost 2012; 107: 409-416. DOI:10.1160/TH11-10-0717.
56 Megens RT, Vijayan S, Lievens D. et al. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost 2012; 107: 597-598. DOI:10.1160/TH11-09-0650.
57 Bird JE, Smith PL, Wang X. et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012; 107: 1141-1150. DOI:10.1160/TH-11-10-0682.
58 Boulaftali Y, Lamrani L, Rouzaud MC. et al. The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy. Thromb Haemost 2012; 107: 962-971. DOI:10.1160/TH11-10-0705.
59 Fish RJ, Vorjohann S, Béna F. et al. Developmental expression and organisation of fibrinogen genes in the zebrafish. Thromb Haemost 2012; 107: 158-166. DOI:10.1160/TH11-04-0221.
60 Lip GY, Weber C. Clinical and basic science articles from Thrombosis and Haemostasis. Thromb Haemost 2011; 105: 202-205.